Erisipelias and its Management in a Tertiary Care Hospital

Mayra, Evelyn Quinones Martinez¹, Charit nayelly chang Cruz², Kim Rodriguez Relingh³

¹,²,³Department of internal medicine high specialty hospital of veracruz, sesver, veracruz, Mexico Av. 20 de noviembre 1074, ver, ver

ABSTRACT

Erisipelias is an acute dermo-hypodermic (non-necrotizing) infection of bacterial origin, mainly group A beta-hemolytic streptococcus. The lower limbs are affected in more than 80% of cases and the risk factors identified are skin barrier breakdown, lymphedema and obesity. Diagnosis is clinical and is based on the association of an acute inflammatory plaque with fever, lymphangitis, lymphadenopathy and leukocytosis. Bacteriology is generally not useful due to low sensitivity or late positivity. In atypical forms, erisipelias should be distinguished from necrotizing fasciitis and acute venous thrombosis. Penicillin remains the gold standard treatment, although new drugs may be used, given their pharmacodynamic profile. Recurrence is the main complication, being crucial the correct treatment of risk factors¹.

INTRODUCTION

Erisipelias is a cutaneous bacterial infection caused by group A beta-hemolytic streptococcus or Streptococcus pyogenes (S. pyogenes) or, more rarely, Staphylococcus aureus (S. aureus). It is characterized by the presence of acute inflammatory signs (erythema, edema, heat and local pain) in the cutaneous integument, often associated with systemic symptoms of malaise, chills and fever. It diffusely affects the dermis and the superficial part of the subcutaneous cellular tissue, being important the involvement of local lymphatic vessels. Its preferred locations are the lower extremities, centrofacial area and auricular pavilions.²

EPIDEMIOLOGY

Erisipelias is a frequent pathology. The incidence rate varies from 0.2/1000 to 24.6/1000 persons per year in different populations. They affect the lower extremity in approximately 80% of cases, and can also occur on the upper extremities, face and trunk.³ Lesions of the upper extremity are associated with intravenous drug users and women undergoing axillary lymphadenectomy for breast cancer (with an incidence that can reach 24%).⁴ Facial erisipelias in children has decreased in recent decades, erisipelias of the upper extremities after breast surgery, and erisipelias of the erisipelias on the upper extremities after breast surgery are also becoming rarer because surgical procedures are becoming less and less invasive.⁵ They are more frequently seen in elderly, immunocompromised patients, and with underlying pathologies that will be mentioned throughout the article.⁶

CLINICAL MANIFESTATIONS

Erisipelias begins as a localized area of erythema and edema, painful, with raised borders and spreads rapidly with active periphery. The distinguishing features of classic erisipelias are red, edematous (orange peel-like) lesions, raised margins and clear contrast with healthy skin, which is often accompanied by systemic symptoms two to three days after inoculation, such as fever, chills, lymphangitis and regional lymphadenopathy, and often the gateway is found to be trauma (often unnoticed by the patient), abrasions, eczematous lesions or more frequently superficial mycosis. Bacteremia is present in less than 5% of cases. Sometimes it is accompanied by vesicles or blisters that may be hemorrhagic (erisipelias bullosa), especially in elderly or immunosuppressed patients, complicating the natural course. Another variant is erisipelias phlegmonosa, considered the most severe form, in which abscesses are formed and then necrosis.⁷,⁸,⁹,¹⁰

DIAGNOSIS

The diagnosis of erisipelias is based on the association of an acute inflammatory plaque with fever, lymphangitis, adenopathy and hyperleukocytosis. These associated
Erysipelas and its Management in a Tertiary Care Hospital

symptoms are variable (20-70 p. 100 of cases). Bacteriology is not useful for the diagnosis of erysipelas due to its low sensitivity (blood culture 5 p. 100, standard tests 5-41 p. 100) or late positivity (serology). In addition, skin bacteriology is difficult to evaluate when bacteria other than streptococci are isolated. Erysipelas should be distinguished from nonnecrotizing cellulitis by peculiar clinical features (such as erysipeloid, staphylococcal facial infection, Pasteurella, Haemophilus influenzae) and necrotizing fasciitis. Some non-infectious diseases can mimic erysipelas, such as venous thrombosis, familial Mediterranean fever, prosthesis intolerance and compartment syndrome. Because the diagnostic value of clinical symptoms is unknown and no diagnostic gold standard has been established, it is impossible to be certain that nonstreptococcal (especially staphylococcal) erysipelas actually exists. Therefore, the first-line treatment for all erysipelas should be an antistreptococcal antibiotic. Before prescribing treatment, blood culture and blood count may be helpful. If antistreptococcal antibiotic therapy is ineffective, all differential diagnoses should be reviewed.11

TREATMENT

The treatment for erysipelas will initially be local measures, such as immobilization and subsequent elevation of the area that is affected to reduce edema, also cold compresses with sodium chloride or sterile saline will be used, which will considerably reduce pain because they are astringent agents in the presence of blisters. If the physical treatment does not produce improvement, antibiotic treatment will be started empirically, which can be modified according to the evolution of the patient and depending on the result of cultures in case of taking them, it will be started for mild cases with cloxacillin 500 mg every 6 hours, later azithromycin 500 mg every 24H or clarithromycin 500 mg every 12H will be used.12,13,14,15 If methicillinresistant S. Aureus has been cultivated, the treatment will be changed to cotrimoxazole at a rate of 80mg/400mg two tablets every 12 hours + rifampicin 600 mg every 24 hours or it has been shown that the use of ciprofloxacin 500 mg every 12 hours or the use of fusidic acid 500 mg every 8 hours are well tolerated by patients and the evolution tends to be positive.16 In patients with evolved erysipelas occupying a large area and with associated underlying pathologies, they should be hospitalized and treated with intravenous benzathine penicillin G at a rate of 1000000 to 2,000000 IU every 4-6 H. If the causal agent is suspected to be staphylococcal, semisynthetic penicillin resistant penicillin such as cloxacillin at a rate of 2g every 4 hours intravenous or cefazolin at a rate of 1g every 8h intravenous should be administered. And in cases of methicillin-resistant S. aureus, vancomycin will be used at a rate of 500 mg every 6 hours or 1 g every 12 hours17.

CONCLUSIONS

In conclusion, treatment of erysipelas is based on the severity of the disease and the age of the patient. Topical treatments are the first line of treatment for most patients with mild to moderate erysipelas. Systemic treatments are reserved for patients with severe erysipelas with systemic involvement who do not respond to topical treatments. The search for new treatments is challenging for hospital-based health care personnel.

REFERENCES

Erisipelas and its Management in a Tertiary Care Hospital


XIV. Swartz MN. Cellulitis. 2004;904–12.


XVII. Bd B, KI HW. Cellulitis Pathophysiology Treatment / Management Differential Diagnosis. 2020;1–5